Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Biosensors International has announced four- year results from the BioFreedom First in Man study (FIM), which demonstrated similar clinical outcomes between BioFreedomTM, a polymer-free drug-coated stent (DCS), and Boston Scientific's TaxusTM LibertĂ©TM drug-eluting stent (DES), with no evidence of definite and/or probable stent thrombosis. Results were presented by Dr. Ricardo Costa, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, sponsored by the Cardiovascular Research Foundation.
BioFreedom represents the latest development in Biosensors' stent technology, featuring a micro-structured abluminal surface which permits the controlled release of Biolimus A9TM (BA9TM) without the use of a polymer. BA9 is a highly lipophilic antirestenotic drug developed by Biosensors specifically for use with stents.
In this First in Man ('FIM') study, 182 patients were randomized into three equally sized treatment groups: BioFreedom; a low-dose formulation of BioFreedom that is not being commercialized; and Taxus LibertĂ©. 93.5% of enrolled patients were followed up at four years.
At four years, the rate of MACE (a composite of all death, MI, emergent cardiac artery bypass graft (CABG) and target lesion revascularization (TLR)) observed in patients treated with BioFreedom was not significantly different from that observed in patients treated with Taxus LibertĂ© (13.6% vs. 13.3%: p= non-significant (>0.05)). TLR was performed nearly half as often on patients treated with BioFreedom as on those treated with Taxus LibertĂ© (5.2% vs. 10.2% p= non-significant (>0.05)).
BioFreedom demonstrated sustained safety up to four years, including absence of definite and/or probable stent thrombosis.
Another important trial - LEADERS FREE - has been designed to assess the potential for a DCS to deliver the anti-restenotic benefits of a DES while giving a shorter one-month course of DAPT, currently only recommended for a bare-metal stent (BMS). It is the world's first prospective, randomised double-blind trial between a DCS and BMS, exclusively involving patients at high risk of bleeding. Patients in both arms of the study are being prescribed only one month of DAPT, although they are taking a single anti-platelet drug indefinitely.
Approximately 2,500 patients are being enrolled in the study at 65 sites across Europe, Asia and South America, with follow-up scheduled for two years. 1,000 patients have been enrolled to date. Investigators anticipate completing the enrollment process by early 2014. Primary endpoint data is likely to be presented during 2015.
In January this year, BioFreedom received CE Mark approval, supported by strong primary endpoint data from the earlier-mentioned FIM study. At 12 months, BioFreedom was non- inferior (pnon-inferiority=0.001) to Taxus LibertĂ© in terms of Late Lumen Loss, with a trend towards superiority (p=0.11). Median in-stent late lumen loss in patients receiving BioFreedom was reduced to 0.17 mm as compared with a median in-stent late lumen loss of 0.35 mm in the Taxus LibertĂ© group.
BioFreedom is in the process of being launched in selected markets, with a full commercial launch anticipated during 2014.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Cardiovascular / Cardiology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
International, Biosensors. "BioFreedom continues to demonstrate comparable long-term safety and efficacy to conventional DES." Medical News Today. MediLexicon, Intl., 5 Nov. 2013. Web.
6 Dec. 2013. <http://www.medicalnewstoday.com/releases/268341>
International, B. (2013, November 5). "BioFreedom continues to demonstrate comparable long-term safety and efficacy to conventional DES." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/268341.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.